Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 14, 2026, 6:40 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 649–672 of 849 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Prospective Blood Draw Clear all

Conditions: Breast Carcinoma, Cardiomyopathy, Congestive Heart Failure
Interventions: Biospecimen Collection, Electronic Medical Record; Procedure · Other
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years and older
Enrollment: 200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2030
U.S. locations: 2
States / cities: Gainesville, Florida • Jacksonville, Florida

Conditions: Eosinophilia, Hypereosinophilic Syndrome
Interventions: Not listed
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 1 Year to 100 Years
Enrollment: 50 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: Started 2005
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Intracranial Hypertension
Interventions: HS-1000 recording; Device
Lead sponsor: HeadSense Medical; Industry
Eligibility: Up to 18 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016
U.S. locations: 1
States / cities: Akron, Ohio

Conditions: Prostate Cancer Detection
Interventions: Proclarix; Diagnostic Test
Lead sponsor: Sequenom, Inc.; Industry
Eligibility: 40 Years to 75 Years · Male only
Enrollment: 500 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 7
States / cities: San Diego, California • Meridian, Idaho • Bowling Green, Kentucky + 4 more

Conditions: Dry Eye, Eye Diseases, Eyes Dry Chronic
Interventions: Autologous Serum Tears (50% Autologous Serum Tears + 0.2% Sodium Hyaluronate), Biological - Autologous Serum Tears (50% Autologous Serum Tears + Balanced Saline Solution (BSS), Standard of Care (SOC) Treatment; Biological · Other
Lead sponsor: University of Miami; Other
Eligibility: 18 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 1
States / cities: Miami, Florida

Conditions: Congestive Heart Failure (CHF)
Interventions: Not listed
Lead sponsor: Nanogen, Inc.; Industry
Eligibility: 45 Years and older
Enrollment: 450 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008
U.S. locations: 2
States / cities: San Diego, California • San Francisco, California

Conditions: Pancreatic Cancer, Pancreatic Cyst
Interventions: Blood Sample collection, Tissue sample collection, Data collection; Other
Lead sponsor: H. Lee Moffitt Cancer Center and Research Institute; Other
Eligibility: 18 Years and older
Enrollment: 1,274 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2026
U.S. locations: 3
States / cities: Lakewood Rch, Florida • Miami, Florida • Tampa, Florida

Conditions: Glioblastoma (GBM)
Interventions: Ketogenic Diet, Radiation therapy, Temozolomide; Dietary Supplement · Radiation · Drug
Lead sponsor: St. Joseph's Hospital and Medical Center, Phoenix; Other
Eligibility: 18 Years to 80 Years
Enrollment: 14 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2017
U.S. locations: 1
States / cities: Phoenix, Arizona

Conditions: Fertility, SPERM, Cancer
Interventions: Sperm and blood collected for analysis; Procedure
Lead sponsor: University of Tennessee; Other
Eligibility: 13 Years and older · Male only
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2020
U.S. locations: 1
States / cities: Memphis, Tennessee

Conditions: Cancer, Chemotherapeutic Toxicity, Coronary Artery Disease, Coronary Microvascular Disease
Interventions: Not listed
Lead sponsor: University of California, Los Angeles; Other
Eligibility: 18 Years and older
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2027
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: SARS-CoV-2, COVID-19
Interventions: Sample collection; Other
Lead sponsor: COVID-19 Prevention Network; Network
Eligibility: 18 Years and older
Enrollment: 953 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2022
U.S. locations: 15
States / cities: Birmingham, Alabama • San Francisco, California • Miami, Florida + 11 more

Conditions: Traumatic Brain Injury
Interventions: Blood draw; Other
Lead sponsor: Banyan Biomarkers, Inc; Industry
Eligibility: 18 Years and older
Enrollment: 194 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2017
U.S. locations: 7
States / cities: Gainesville, Florida • Orlando, Florida • Detroit, Michigan + 3 more

Conditions: Polycythemia Vera, ET (Essential Thrombocythemia), Polycythemia Vera (PV), Essential Thrombocythemia (ET), Primary Myelofibrosis (MF), Primary Myelofibrosis (PMF), Myelofibrosis, Myelofibrosis (MF), Myelofibrosis, Primary, Myelofibrosis, Post ET, Myelofibrosis, Post PV, Myelofibrosis (PMF), Myelofibrosis，MF, Myelofibrosis; Primary Myelofibrosis; Post-polycythemia Vera Myelofibrosis; Post-essential Thrombocythemia Myelofibrosis, Myelofibrosis Due to and Following Polycythemia Vera, Myelofibrosis Transformation in Essential Thrombocythemia, Myelofibrosis With High Molecular Risk Mutations, MF, Secondary Myelofibrosis, Secondary Myelofibrosis in Myeloproliferative Disease, Secondary Myelofibrosis (Post-Polycythemia Vera Myelofibrosis, Post-Essential Thrombocythemia Myelofibrosis), Post-Polycythemia Vera Myelofibrosis, Post-polycythemia Vera Myelofibrosis (PPV-MF), Post-polycythemia Vera Myelofibrosis (Post-PV MF), Post-polycythemia Vera Myelofibrosis(Post-PV MF), Post-PV MF, Post-Essential Thrombocythemia Myelofibrosis, Post-essential Thrombocythemia Myelofibrosis (PET-MF), Post-essential Thrombocythemia Myelofibrosis(Post-ET MF), Post-essential Thrombocythemia Myelofibrosis (Post-ET MF), Post-ET MF, Pre-fibrotic Myelofibrosis, Myeloproliferative Disorder, Myeloproliferative Disorders, Myeloproliferative Disorders (MPD), Myeloproliferative Neoplasms (MPNs), Myeloproliferative Neoplasm(MPN)-Associated Myelofibrosis, Myeloproliferative Neoplasm With 10% Blasts or Higher, Myeloproliferative Neoplasms, MPN, MPN (Myeloproliferative Neoplasms), MPN-associated Myelofibrosis, Myeloproliferative Neoplasm, Unclassifiable, Myeloproliferative Neoplasm, Not Otherwise Specified, Accelerated Phase MPN, Accelerated Phase Myeloproliferative Neoplasm, Blast Phase MPN, Blast Phase Myeloproliferative Neoplasm, Thrombocythemia Myelofibrosis (PET-MF), Thrombocythemia, Essential, Thrombocythemia, Hemorrhagic, Agnogenic Myeloid Metaplasia, Chronic Idiopathic Myelofibrosis, Idiopathic Myelofibrosis, MDS/MPN Crossover Syndromes
Interventions: Not listed
Lead sponsor: MPN Research Foundation; Other
Eligibility: 18 Years and older
Enrollment: 5,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2035
U.S. locations: 2
States / cities: Chicago, Illinois • New York, New York

Conditions: Hepatitis
Interventions: Not listed
Lead sponsor: National Institutes of Health Clinical Center (CC); NIH
Eligibility: Not listed
Enrollment: 2,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1981 – 2000
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Alveolar Ridge Preservation, Tooth Extraction
Interventions: Leukocyte platelet rich fibrin plug + d-PTFE membrane, d-PTFE membrane; Biological · Device
Lead sponsor: Firas Al Yafi; Other
Eligibility: 18 Years to 80 Years
Enrollment: 27 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2020
U.S. locations: 1
States / cities: Lexington, Kentucky

Conditions: Glycogen Storage Disease Type IB
Interventions: Specimen Donation; Diagnostic Test
Lead sponsor: Sanguine Biosciences; Industry
Eligibility: 4 Years to 85 Years
Enrollment: 6 participants
Timeline: 2023 – 2024
U.S. locations: 1
States / cities: Woburn, Massachusetts

Conditions: Atrial Fibrillation, Post-Op Complication
Interventions: CardiaMend in Combination with Amiodarone; Combination Product
Lead sponsor: University of Chicago; Other
Eligibility: 20 Years to 85 Years
Enrollment: 63 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Chronic Primary Immune Thrombocytopenia (ITP)
Interventions: Kedrion IVIG 10%; Biological
Lead sponsor: Kedrion S.p.A.; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 3
States / cities: Los Angeles, California • Shirley, New York • Greenville, North Carolina

Conditions: Pancreatic Adenocarcinoma
Interventions: Blood Specimen; Diagnostic Test
Lead sponsor: Beth Israel Deaconess Medical Center; Other
Eligibility: 50 Years to 100 Years
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2024
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Peripheral Arterial Disease
Interventions: DETOUR System; Device
Lead sponsor: Endologix; Industry
Eligibility: 18 Years to 90 Years
Enrollment: 202 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2023
U.S. locations: 30
States / cities: Scottsdale, Arizona • Jonesboro, Arkansas • Little Rock, Arkansas + 27 more

Conditions: Von Willebrand Disease
Interventions: von Willebrand factor (Recombinant), Antihemophilic Factor (Recombinant); Biological
Lead sponsor: Takeda; Industry
Eligibility: 18 Years and older
Enrollment: 29 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2020
U.S. locations: 8
States / cities: Loveland, Colorado • Gainesville, Florida • Jacksonville, Florida + 5 more

Conditions: Acetabular Labrum Tear
Interventions: PRP; Biological
Lead sponsor: University of Utah; Other
Eligibility: 18 Years to 49 Years
Enrollment: 30 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2026
U.S. locations: 1
States / cities: Salt Lake City, Utah

Conditions: Trauma Injury
Interventions: Prothrombin Complex Concentrate, Human, Placebo; Drug
Lead sponsor: Oregon Health and Science University; Other
Eligibility: 18 Years and older
Enrollment: 166 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2025
U.S. locations: 1
States / cities: Portland, Oregon

Conditions: Cardiac Perfusion
Interventions: del Nido solution, Blood-based cardioplegia; Other
Lead sponsor: Inova Health Care Services; Other
Eligibility: 19 Years to 79 Years
Enrollment: 99 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2017
U.S. locations: 2
States / cities: Falls Church, Virginia

Search by objective public record fields.

TRPC6 Characterization to Predict and Prevent Chemotherapy Related Cardiomyopathy and Heart Failure With Breast Cancer

A Longitudinal Study of Familial Hypereosinophilia (FE): Natural History and Markers of Disease Progression

Non-invasive Intracranial Pressure (ICP) Monitoring in Pediatric Patients

Prostate Cancer Risk Identification in a Multi-Ethnic Cohort: a Prospective US-based Multi-center Validation Study of Proclarix

Autologous Serum Tears With Hyaluronate vs Balanced Salt Solution for Moderate-to-Severe Dry Eye

Prospective Evaluation of the StatusFirst™ CHF NT-proBNP Device in Human Whole Blood and Plasma Samples

Using Radiogenomics to Predict Malignant Potential of Intraductal Papillary Mucinous Neoplasms of the Pancreas

Ketogenic Diet With Radiation and Chemotherapy for Newly Diagnosed Glioblastoma

Male Fertility and Sperm Cryopreservation

Serial PET MPI in Patients Undergoing Cancer Treatment

A Study of Immune Responses to the Virus That Causes COVID-19

Evaluation of Biomarker Kinetics After Mild Brain Injury Trauma

MPN PROGRESSion Registry: Observational Study Tracking Symptoms, Treatments, and Disease Progression in People With Myeloproliferative Neoplasms (MPNs)

A Controlled Prospective Study of Transfusion-Associated Hepatitis

A 14 Weeks Longitudinal Study to Investigate the Effect of Leukocyte- Platelet Rich Fibrin Plug on the Quality of the Newly Formed Bone in Ridge Preservation Procedure Following a Tooth Extraction. It is a Clinical, Radiographic and Histomorphometric Study.

Prospective Collection of Biospecimen in Pediatric Patients and Adult Guardians Diagnosed With Glycogen Storage Disease Type 1B (GSD1b)

Prevention of Postoperative Atrial Fibrillation (POAF) Using Intra-Pericardial Amiodarone

A Study Investigating Intravenous Human Normal Immunoglobulin 10% in Adults With Chronic Immune Thrombocytopenia (ITP)

Panc CA Risk Model & Biomarker Testing In High-Risk Cohort

The DETOUR 2 Clinical Trial

rVWF IN PROPHYLAXIS

Intra-articular Platelet-Rich Plasma for Acetabular Labral Tears

Prehospital Kcentra for Hemorrhagic Shock

Del Nido Cardioplegia Randomized Trial